Terms: = Prostate cancer AND PAM50
17 results:
1. [Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer].
Wikström P; Bergh A; Josefsson A; Thysell E; Welén K
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38656744
[TBL] [Abstract] [Full Text] [Related]
2. Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance.
Ross AE; Iwata KK; Elsouda D; Hairston J; Russell D; Davicioni E; Proudfoot JA; Shore ND; Schaeffer EM
JCO Precis Oncol; 2024 Apr; 8():e2300603. PubMed ID: 38635932
[TBL] [Abstract] [Full Text] [Related]
3. Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy.
Ge Q; Li J; Yang F; Tian X; Zhang M; Hao Z; Liang C; Meng J
Ann Med; 2023; 55(2):2279235. PubMed ID: 37939258
[TBL] [Abstract] [Full Text] [Related]
4. pam50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?
Haywood SC; Gupta S; Heemers HV
Eur Urol Focus; 2022 Jul; 8(4):916-918. PubMed ID: 36031559
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant prostate cancer.
Coleman IM; DeSarkar N; Morrissey C; Xin L; Roudier MP; Sayar E; Li D; Corey E; Haffner MC; Nelson PS
Clin Cancer Res; 2022 Jul; 28(14):3127-3140. PubMed ID: 35552660
[TBL] [Abstract] [Full Text] [Related]
6. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy.
Grass GD; Alfonso JCL; Welsh E; Ahmed KA; Teer JK; Pilon-Thomas S; Harrison LB; Cleveland JL; Mulé JJ; Eschrich SA; Enderling H; Torres-Roca JF
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):635-647. PubMed ID: 35289298
[TBL] [Abstract] [Full Text] [Related]
7. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
[TBL] [Abstract] [Full Text] [Related]
8. Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients.
Belluti S; Semeghini V; Rigillo G; Ronzio M; Benati D; Torricelli F; Reggiani Bonetti L; Carnevale G; Grisendi G; Ciarrocchi A; Dominici M; Recchia A; Dolfini D; Imbriano C
J Exp Clin Cancer Res; 2021 Nov; 40(1):362. PubMed ID: 34782004
[TBL] [Abstract] [Full Text] [Related]
9. Identification of DNA Damage Repair-Associated Prognostic Biomarkers for prostate cancer Using Transcriptomic Data Analysis.
Teng PC; Huang SP; Liu CH; Lin TY; Cho YC; Lai YL; Wang SC; Yeh HC; Chuu CP; Chen DN; Cheng WC; Li CY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769200
[TBL] [Abstract] [Full Text] [Related]
10. A comparative study of PCS and pam50 prostate cancer classification schemes.
Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
[TBL] [Abstract] [Full Text] [Related]
11. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract] [Full Text] [Related]
12. Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly prostate cancer Patients with Low-grade Disease.
Goldberg H; Spratt D; Chandrasekar T; Klaassen Z; Wallis CJD; Santiago-Jimenez M; Fishbane N; Davicioni E; Noorani R; Ahmad AE; Herrera Cáceres JO; Alibhai S; Berlin A; Fleshner NE
Eur Urol Focus; 2021 Jul; 7(4):797-806. PubMed ID: 32156491
[TBL] [Abstract] [Full Text] [Related]
13. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.
Zhao SG; Chen WS; Das R; Chang SL; Tomlins SA; Chou J; Quigley DA; Dang HX; Barnard TJ; Mahal BA; Gibb EA; Liu Y; Davicioni E; Duska LR; Posadas EM; Jolly S; Spratt DE; Nguyen PL; Maher CA; Small EJ; Feng FY
Clin Cancer Res; 2019 Apr; 25(8):2450-2457. PubMed ID: 30573691
[TBL] [Abstract] [Full Text] [Related]
14. The Diverse Genomic Landscape of Clinically Low-risk prostate cancer.
Cooperberg MR; Erho N; Chan JM; Feng FY; Fishbane N; Zhao SG; Simko JP; Cowan JE; Lehrer J; Alshalalfa M; Kolisnik T; Chelliserry J; Margrave J; Aranes M; Plessis MD; Buerki C; Tenggara I; Davicioni E; Carroll PR
Eur Urol; 2018 Oct; 74(4):444-452. PubMed ID: 29853306
[TBL] [Abstract] [Full Text] [Related]
15. Associations of Luminal and Basal Subtyping of prostate cancer With Prognosis and Response to Androgen Deprivation Therapy.
Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
[TBL] [Abstract] [Full Text] [Related]
16. The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype.
Need EF; Selth LA; Trotta AP; Leach DA; Giorgio L; O'Loughlin MA; Smith E; Gill PG; Ingman WV; Graham JD; Buchanan G
BMC Cancer; 2015 Oct; 15():791. PubMed ID: 26498662
[TBL] [Abstract] [Full Text] [Related]
17. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data.
Koch A; De Meyer T; Jeschke J; Van Criekinge W
BMC Genomics; 2015 Aug; 16(1):636. PubMed ID: 26306699
[TBL] [Abstract] [Full Text] [Related]
